CDEK
← All drugs Report issue

yellow fever vaccine 17d strain

Vaccineapproved

Approved

May 22, 1953

Yellow fever vaccine is a vaccine that protects against yellow fever. Yellow fever is a viral infection that occurs in Africa and South America. Most people begin to develop immunity within ten days of vaccination and are 99% protected within one month, and this appears to be lifelong. The vaccine can be used to control outbreaks of disease. It is given either by injection into a muscle or just under the skin. — Wikipedia

Clinical trial activity

47 trials · 53 clinical orgs · 1 marketing orgs

Phase 1
10
Phase 2
25
Phase 3
11
Phase 4
11

Earliest trial started Jul 1, 2004 (NCT00982137)

Timeline

1930s

  1. Jul 1, 1935

    Evidence of US Marketing

1950s

  1. May 22, 1953

    Earliest FDA Approval

1990s

  1. Dec 9, 1999

    Sanofi-Aventis — First NDA Organization

  2. Dec 9, 1999

    Sanofi-Aventis — NDA Secondary Org

  3. Dec 9, 1999

    Sanofi-Aventis — NDA Organization

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Biological vaccine - induces immune response

  • Yellow fever virusImmunity, active

    Yellow fever virus immunity, active

Approval history

  • approvedMay 22, 1953
  • approvedJul 1, 1935

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • flavivirus yellow fever virus 17d-204 whole
  • inactivated yellow fever vaccine
  • live attenuated yellow fever vaccine
  • mva-bn yellow fever vaccine
  • stamaril
  • yellow fever, live attenuated
  • yellow fever, live attenuated
  • yellow fever vaccine
  • yellow fever vaccine
  • yellow fever vaccine
  • yellow fever vaccine
  • yellow fever vaccine 17d strain
  • yellow fever vaccine, live, 17d
  • yellow fever virus 17d/tiantan live antigen
  • yellow fever virus live antigen, a
  • yellow fever virus strain 17d-204 live antigen
  • yellow fever virus strain 17d-204 live (attenuated) antigen
  • yellow fever virus strain 17d (live, attenuated)
  • yellow fever virus vaccine
  • yfv-17d
  • yf-vax
  • yf-vax
  • yf-vax

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07222059Phase 3Oct 23, 2025Sanofi-Aventis
NCT07103148Phase 3Jul 11, 2025Sanofi
NCT06879327Phase 2May 30, 2025PATH, Pharmassist Ltd
NCT07002060Phase 3May 22, 2025Sanofi
NCT06815835Phase 3Apr 1, 2025International Center for Diarrheal Disease Research, Zydus Discovery DMCC
NCT06399003Phase 3Jun 28, 2024China National Biotec Group Co., Ltd
NCT06213506Phase 2Jan 15, 2024GlaxoSmithKline, Kwame Nkrumah University of Science and Technology
NCT06148025Phase 4Nov 30, 2023Flinders University, South Australian Health and Medical Research Institute, Telethon Kids Institute, University of Adelaide, University of Sydney
NCT05859490Phase 1/Phase 2 (Phase 2)Aug 1, 2023Oregon Health and Science University
NCT05801978Phase 4Apr 11, 2023Defense Advanced Research Projects Agency, Emory University
NCT05901454N/AFeb 17, 2023Leiden University
NCT05468606Early Phase 1 (Phase 1)Jan 31, 2023Leiden University
NCT05568953Phase 2Oct 31, 2022Duke University, Singapore General Hospital
NCT05447377Phase 3Jul 30, 2022Serum Institute of India Pvt. Ltd.
NCT05421611Phase 3Jul 25, 2022Serum Institute of India Pvt. Ltd.
NCT05450770N/AJul 1, 2022Government of France, University of Paris
NCT05332197Phase 3May 16, 2022University of London
NCT05155579Phase 1Feb 28, 2022Malaria Research and Training Center, Bamako, Mali, University of Oxford
NCT05011123Phase 2Oct 7, 2021Sanofi, Sanofi-Aventis
NCT04942210Phase 2Jul 1, 2021Sanofi-Aventis
Showing 20 of 47 trials
Page 1 / 3

Organizations

Research & Development (53)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sanofi-AventisFor profit6432006
SanofiFor profit5422004
Emory UniversityAcademic/Hospital4432006
GlaxoSmithKlineFor profit4422007
National Institute of Allergy and Infectious Diseases (NIAID)Government4322008
Centers for Disease Control and Prevention (CDC)Government3122006
PATHAcademic/Hospital3222011
EpicentreFor profit2112017
Leiden UniversityAcademic/Hospital2222023
Medical Research Council-UVRI Uganda Research Unit on AIDSAcademic/Hospital2012018
Oregon Health and Science UniversityAcademic/Hospital2112008
Oswaldo Cruz FoundationAcademic/Hospital2212016
Serum Institute of India Pvt. Ltd.For profit2212022
Singapore General HospitalAcademic/Hospital2212017
University of LondonAcademic/Hospital2122011
University of OxfordAcademic/Hospital2222019
University of ParisAcademic/Hospital2022011
Aarhus UniversityAcademic/Hospital1112019
Centre for Vaccine Development, MaliAcademic/Hospital1012014
China National Biotec Group Co., LtdFor profit1112024
53 organizations
Page 1 / 3

Marketing (2)

OrganizationOrg typeRelationshipDate
Sanofi-AventisFor profitNDA2Dec 9, 1999
Sanofi-AventisFor profitNDADec 9, 1999